Online inquiry

IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8890MR)

This product GTTS-WQ8890MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets IFNA1; IFNB1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_024013.3; NM_002176.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439; 3456
UniProt ID P01562; P01574
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8890MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3782MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ13081MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ6025MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ6034MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ11632MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ15288MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ6891MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ3619MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1179470
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW